Table A5. Sensitivity analyses for primary and secondary outcomes of mould-active vs fluconazole prophylaxis.

	Analyses for all included studies		Sensitivity analysis-studies of itraconazole capsules removed (Annaloro et al, 1995; Huijgens et al, 1999b)
Outcome	Risk ratio* (95% CI)	P-value	Risk ratio* (95% CI)	P-value
Proven or probable IFI	0.71 (0.52, 0.98)	0.03	0.68 (0.49, 0.94)	0.02
Invasive aspergillosis	0.53 (0.37, 0.75)	0.0004	0.50 (0.35, 0.71)	0.0001
Adverse events requiring antifungal treatment discontinuation or modification	1.95 (1.24, 3.07)	0.004	1.95 (1.24, 3.07)	0.004
IFI-related mortality	0.67 (0.47, 0.96)	0.03	0.62 (0.43, 0.90)	0.01
Invasive aspergillosis-related mortality	0.62 (0.23, 1.71)	0.36	0.41 (0.12, 1.39)	0.15
Overall mortality	1.00 (0.88, 1.13)	0.96	0.99 (0.87, 1.13)	0.85
			Sensitivity analysis-studies of Itraconazole 200 mg per day removed (Choi et al, 2005; Ito et al, 2007b; Ota et al, 2010)
Proven or probable IFI	0.71 (0.52, 0.98)	0.03	0.72 (0.53, 0.99)	0.05
Invasive aspergillosis	0.53 (0.37, 0.75)	0.0004	0.54 (0.38, 0.76)	0.0005
Adverse events requiring antifungal treatment discontinuation or modification	1.95 (1.24, 3.07)	0.004	1.85 (1.13, 3.03)	0.01
IFI-related mortality	0.67 (0.47, 0.96)	0.03	0.66 (0.46, 0.95)	0.02
Invasive aspergillosis-related mortality	0.62 (0.23, 1.71)	0.36	0.62 (0.23, 1.71)	0.36
Overall mortality	1.00 (0.88, 1.13)	0.96	1.00 (0.88, 1.14)	0.98

Abbreviations: CI=confidence interval; IFI=invasive fungal infection. *RR<1 represents an advantage of mould-active coverage compared with fluconazole using a random-effects model.